Target Price | €44.70 |
Price | €41.35 |
Potential | 8.12% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €44.70. This is 8.12% higher than the current stock price. The highest price target is €51.36 24.23% , the lowest is €39.00 5.66% . | |
A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 8.12% . Most analysts recommend the Qiagen stock at Buy or hold. |
24 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 4.11% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 7.75% , the lowest is €1.7b 2.51% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 7.37% |
2026 | €1.9b | 5.74% |
2027 | €2.0b | 6.68% |
2028 | €2.3b | 12.35% |
2029 | €2.5b | 9.25% |
2030 | €2.9b | 14.08% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €674m . This is 41.77% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €752m 57.68% , the lowest is €601m 26.03% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €433m | 10.64% |
---|---|---|
2025 | €674m | 56.13% |
2026 | €724m | 7.50% |
2027 | €783m | 8.01% |
2028 | €835m | 6.72% |
2029 | €891m | 6.75% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.09% | 45.42% |
2026 | 37.70% | 1.64% |
2027 | 38.17% | 1.25% |
2028 | 36.26% | 5.00% |
2029 | 35.43% | 2.29% |
25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €448m . This is 40.15% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €538m 67.78% , the lowest is €421m 31.46% .
This results in the following potential growth metrics and future Net Margins:
2024 | €71.7m | 75.51% |
---|---|---|
2025 | €448m | 525.98% |
2026 | €484m | 8.02% |
2027 | €526m | 8.84% |
2028 | €579m | 10.03% |
2029 | €628m | 8.39% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.64% | 483.09% |
2026 | 25.17% | 2.15% |
2027 | 25.68% | 2.03% |
2028 | 25.15% | 2.06% |
2029 | 24.95% | 0.80% |
25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.06 . This is 42.07% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.48 69.86% , the lowest is €1.94 32.88% .
This results in the following potential growth metrics and future valuations:
2024 | €0.33 | 74.81% |
---|---|---|
2025 | €2.06 | 524.24% |
2026 | €2.23 | 8.25% |
2027 | €2.43 | 8.97% |
2028 | €2.67 | 9.88% |
2029 | €2.90 | 8.61% |
Current | 28.43 | 75.20% |
---|---|---|
2025 | 19.97 | 29.76% |
2026 | 18.48 | 7.46% |
2027 | 16.98 | 8.12% |
2028 | 15.43 | 9.13% |
2029 | 14.24 | 7.71% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 5.14 and an P/S ratio of 4.91 .
This results in the following potential growth metrics and future valuations:
Current | 5.35 | 0.56% |
---|---|---|
2025 | 5.14 | 3.96% |
2026 | 4.86 | 5.43% |
2027 | 4.55 | 6.26% |
2028 | 4.05 | 11.00% |
2029 | 3.71 | 8.47% |
2030 | 3.25 | 12.34% |
Current | 5.11 | 0.95% |
---|---|---|
2025 | 4.91 | 3.95% |
2026 | 4.64 | 5.43% |
2027 | 4.35 | 6.26% |
2028 | 3.87 | 11.00% |
2029 | 3.54 | 8.47% |
2030 | 3.11 | 12.34% |
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.